Daiichi Sankyo Company, Limited

Ryotaku Inoue

Ryuji Hashimoto

Nobuo Machinaga

Jun Chiba

Mamoru Otoyo

To provide a novel compound that has S1P lyase inhibitory ability and induces a reduction in the number of lymphocytes, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Tokyo, Japan

Ryotaku Inoue